{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:41:25Z","timestamp":1795081285586,"version":"4.10.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eururo.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:42:31Z","timestamp":1765975351000},"page":"368-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["[18F]-Fluciclovine or [68Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial"],"prefix":"10.1016","volume":"89","author":[{"given":"Ashesh B.","family":"Jani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal R.","family":"Dhere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subir","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Schreibmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pretesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Hershatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Hanasoge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil T.","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghuveer","family":"Halkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Fielder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayinka A.","family":"Abiodun-Ojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismaheel","family":"Lawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj A.","family":"Master","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas S.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet A.","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.12.003_b0005","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0140-6736(03)12833-4","article-title":"Early prostate cancer: clinical decision-making","volume":"361","author":"Jani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.12.003_b0010","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.12.003_b0015","doi-asserted-by":"crossref","first-page":"175.e1","DOI":"10.1016\/j.urolonc.2024.02.010","article-title":"Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era","volume":"42","author":"Das","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0020","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.juro.2008.08.037","article-title":"The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794","volume":"180","author":"Swanson","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.12.003_b0025","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomized controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.12.003_b0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomized, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.12.003_b0035","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomized, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0040","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomized trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.12.003_b0050","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate-bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomized phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.12.003_b0055","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.12.003_b0060","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2967\/jnumed.117.192476","article-title":"Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer","volume":"58","author":"Hope","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.12.003_b0065","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2967\/jnumed.120.256784","article-title":"Salvage radiotherapy management decisions in postprostatectomy patients with recurrent prostate cancer based on 18F-fluciclovine PET\/CT guidance","volume":"62","author":"Abioudin-Ojo","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.12.003_b0070","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.euo.2021.01.007","article-title":"Use and impact of positron emission tomography\/computed tomography prior to salvage radiation therapy in men with biochemical recurrence after radical prostatectomy: a scoping review","volume":"4","author":"Valle","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0075","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-Fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomized controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.12.003_b0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"Mazzone","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.12.003_b0085","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1097\/RLU.0000000000002703","article-title":"A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET\/CT","volume":"44","author":"Pernthaler","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2025.12.003_b0090","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-Fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0095","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2017.12.011","article-title":"Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials","volume":"100","author":"Vogelius","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.12.003_b0100","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO-25-00274","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: 10-year outcomes of the FLAME trial","volume":"43","author":"Guricova","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2016.10.026","article-title":"The dose-response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis","volume":"121","author":"King","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.715020","article-title":"Feasibility and outcome of PSMA-PET-based dose-escalated salvage radiotherapy versus conventional salvage radiotherapy for patients with recurrent prostate cancer","volume":"11","author":"Vogel","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09\/10 randomized phase 3 trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.12.003_b0120","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijrobp.2019.09.047","article-title":"Toxicity and biochemical outcomes of dose-intensified postoperative radiation therapy for prostate cancer: results of a randomized phase III trial","volume":"106","author":"Qi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.12.003_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1268309","article-title":"Can PSMA PET\/CT help in dose-tailoring in post-prostatectomy radiotherapy?","volume":"13","author":"Champion","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0130","series-title":"Survival analysis: techniques for censored and truncated data","author":"Klein","year":"2003"},{"issue":"8 Suppl","key":"10.1016\/j.eururo.2025.12.003_b0135","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2025.12.003_b0140","doi-asserted-by":"crossref","unstructured":"Dhere VR, Schuster DM, Goyal S, et al. Volumetric changes and acute toxicity with 68Ga prostate specific membrane antigen vs 18F-fluciclovine PET guided post-prostatectomy radiation. Pract Radiat Oncol. In press. https:\/\/doi.org\/10.1016\/j.prro.2025.07.003.","DOI":"10.1016\/j.prro.2025.07.003"},{"key":"10.1016\/j.eururo.2025.12.003_b0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2024.02.013","article-title":"Long-term outcomes and patterns of relapse following high-dose elective salvage radiotherapy and hormone therapy in oligorecurrent pelvic nodes in prostate cancer: OLIGOPELVIS (GETUG-P07)","volume":"87","author":"Vaugier","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.12.003_b0150","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0155","series-title":"NRG-GU008 protocol: randomized phase III trial incorporating apalutamide and advanced imaging into salvage treatment for patients with node-positive prostate cancer after radical prostatectomy (INNOVATE)","author":"NRG Oncology","year":"2025"},{"key":"10.1016\/j.eururo.2025.12.003_b0160","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijrobp.2025.04.002","article-title":"Severe late toxicities (grade 3\u20135) with 13 years of follow-up after hypofractionated postprostatectomy radiotherapy","volume":"23","author":"Ranta","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.12.003_b0165","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/RLU.0000000000004356","article-title":"18F-Fluciclovine PET detected early tumor recurrence in prostatectomy bed with low PSA of 0.3 ng\/mL but negative on 18F-PSMA PET scan","volume":"48","author":"Nguyen","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2025.12.003_b0170","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.euf.2020.12.009","article-title":"Update from PSMA-SRT trial NCT03582774: a randomized phase 3 imaging trial of prostate-specific membrane antigen positron emission tomography for salvage radiation therapy for prostate cancer recurrence powered for clinical outcome","volume":"7","author":"Calais","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.12.003_b0175","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.annonc.2025.01.017","article-title":"Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG\/RTOG 0126 and SAKK 09\/10 trials","volume":"36","author":"Dal Pra","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.12.003_b0180","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the Decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825048572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825048572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:29:46Z","timestamp":1773916186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825048572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0302283825048572"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.12.003","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[18F]-Fluciclovine or [68Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}